- Home
- MGNX vs INCR Comparison
MGNX vs INCR Comparison
Compare MGNX & INCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGNX
- INCR
- Stock Information
- Founded
- MGNX 2000
- INCR 1994
- Country
- MGNX United States
- INCR Israel
- Employees
- MGNX N/A
- INCR N/A
- Industry
- MGNX Biotechnology: Pharmaceutical Preparations
- INCR Biotechnology: Pharmaceutical Preparations
- Sector
- MGNX Health Care
- INCR Health Care
- Exchange
- MGNX Nasdaq
- INCR Nasdaq
- Market Cap
- MGNX 87.7M
- INCR 83.9M
- IPO Year
- MGNX 2013
- INCR N/A
- Fundamental
- Price
- MGNX $1.33
- INCR $1.52
- Analyst Decision
- MGNX Hold
- INCR
- Analyst Count
- MGNX 9
- INCR 0
- Target Price
- MGNX $5.33
- INCR N/A
- AVG Volume (30 Days)
- MGNX 2.0M
- INCR 6.4K
- Earning Date
- MGNX 08-05-2025
- INCR 08-15-2025
- Dividend Yield
- MGNX N/A
- INCR N/A
- EPS Growth
- MGNX N/A
- INCR N/A
- EPS
- MGNX N/A
- INCR N/A
- Revenue
- MGNX $154,050,000.00
- INCR $65,575,323.00
- Revenue This Year
- MGNX N/A
- INCR $69.54
- Revenue Next Year
- MGNX N/A
- INCR $41.75
- P/E Ratio
- MGNX N/A
- INCR N/A
- Revenue Growth
- MGNX 255.31
- INCR N/A
- 52 Week Low
- MGNX $0.99
- INCR $1.17
- 52 Week High
- MGNX $5.77
- INCR $2.62
- Technical
- Relative Strength Index (RSI)
- MGNX 41.45
- INCR 50.58
- Support Level
- MGNX $1.33
- INCR $1.47
- Resistance Level
- MGNX $2.17
- INCR $1.54
- Average True Range (ATR)
- MGNX 0.17
- INCR 0.05
- MACD
- MGNX -0.02
- INCR -0.00
- Stochastic Oscillator
- MGNX 2.38
- INCR 50.00
About MGNX MacroGenics Inc.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.
About INCR Intercure Ltd.
Intercure Ltd is engaged in the research, cultivation, production, and distribution of pharma-grade cannabis-based products. Its products are available in dried inflorescences or liquid oil form, and are marketed through various brands, including Pharmo Cann, Humboldt, Indoor, Space Labs, Canndoc Utopia, Binske, Canndoc Stars, and others. The company has two operating segments, namely Investments in portfolio companies in the biomed sector and Investments in the medical cannabis sector. A majority of its revenue is generated from the Cannabis segment.